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ECONOMIC EVALUATION OF HIV PRE-EXPOSURE PROPHYLAXIS AMONG MEN-WHO-HAVE-SEX-
WITH-MEN IN ENGLAND: SUPPLEMENTARY MATERIAL 
SUPPLEMENTARY MATERIAL 1 
Age distribution of MSM GUM clinic attendees at high HIV risk 
The 5,000 MSM at high HIV risk who were given HIV-PrEP in the first year of our model (calendar 
year 2016) were age stratified according to the ages of HIV negative MSM who attended GUM clinics 
in 2013 and/or 2014 – from the GUMCAD information system [1]. This age distribution is presented 
in Figure A - 1. 
 
Figure A - 1 Age distribution of 5,000 MSM at high HIV risk in year-1 of model (calendar year 2016) 
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SUPPLEMENTARY MATERIAL 2 
HIV-PrEP GUM pathway 
The cost of HIV-PrEP delivery via GUM clinics was estimated using a micro-costing approach. The 
pathway of care for a patient receiving HIV-PrEP via a GUM clinic was derived from the UK PROUD 
trial protocol, with expert opinion input (Professor S McCormack, MRC Clinical Trials Unit at 
University College London, and Dr J Saunders, University College London, personal communications) 
[2]. Detailed pathway unit costs were taken from treatment pathways compiled by Pathway 
Analytics  and modified accordingly, by selecting the steps relevant to HIV-PrEP, and updated with 
current laboratory pathology prices (published HIV test price, and a University College London 
provider-to-provider services tariff 2012-13) and consumables prices obtained from NHS Supply 
Chain [3–6]. A graphical representation of the flow of a patient through the HIV-PrEP management 
pathway at a GUM clinic is illustrated in Figure A - 2. 
 
Individuals given PrEP were assumed to have five clinic visits in year-1.  For MSM at high HIV risk, 
existing BASHH guidelines recommend quarterly STI screens, so a PrEP eligible MSM would require 
one additional visit per year [7].  Only the additional PrEP costs of a month-1 clinic visit and the PrEP 
specific staff time and renal function tests were included as the opportunity cost of clinic resource 
forgone through PrEP provision. This was estimated to cost an additional £176 (€239) per MSM 
during the first year of HIV-PrEP commencement. This covers HIV-PrEP-related costs within 
appointments during the first 12 months, occurring at month 0, 1, 3, 6, and 9. The additional HIV-
PrEP clinic cost of £176 (€239) was calculated by firstly estimating the total cost of the HIV-PrEP 
GUM delivery pathway (£649 (€883), Figure A - 2), minus the recommended number of routine GUM 
clinic attendance for HIV testing and STI screens in MSM at high risk, as recommended by BASHH 
(quarterly, assumed to occur at month 0, 3, 6, and 9, giving a total cost of £473 (€644)) [7]. 
 
Figure A - 2 GUM pathway for the management of a patient on HIV-PrEP, and routine HIV/STI 
screening; costs are undiscounted; Month 3/6/9 costs will repeat for quarterly appointments in 
subsequent years for MSM continuing HIV-PrEP beyond one year, with renal function assessments 
occurring at an annual frequency 
 
 
GUM pathway for HIV-PrEP 
 
Year 1 
 
Month 0 (Baseline, day start HIV-PrEP – assuming patient comes in for routine HIV/STI consultation and is clinically risk assessed for 
HIV-PrEP) 
 
Total cost for this step: £191 [routine £121 + HIV-PrEP-additional £70] 
 
  Pathway step Data source/notes Pathway cost [routine + 
HIV-PrEP-additional] 
1 Patient consultation £76 [£34 + £42] 
 Routine discussion E.g. check recent sexual behaviour, recreational drug use 
 Assess HIV-PrEP eligibility  
 Check for contraindications Contraindications, medical history 
 Start HIV-PrEP if clinically indicated Give 1 month’s supply 
2 HIV/STI tests £92 [£87 + £5] 
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 HIV test negative Routine screen using serology, plus additional Point-Of-
Care-Test in 67% of patients 
 STI test (Chlamydia/Gonorrhoea 3 site 
plus syphilis test) 
Routine screen 
 Hepatitis C test Routine screen every 6 months (serology test considered 
if there is history of recreational drug use/chem sex), 
assume 50% of patients will be screened due to risk[7,8] 
3 Tenofovir disoproxil fumarate 245mg/emtricitabine 200mg (proprietary name Truvada®)  - renal 
function monitoring 
£23 [£0 + £23] 
 Serum creatinine Assessment of renal function prior to HIV-PrEP 
commencement 
 
 
 
 
Month 1 
 
Total cost for this step: £52  [routine £0 + HIV-PrEP-additional £52] 
 
  Pathway step Data source/notes Pathway cost [routine + 
HIV-PrEP-additional] 
1 Patient consultation £44 [£0 + £44] 
 Check drug management Include review of adherence, dosing pattern/frequency 
 Sexual behaviour assessment Any risk compensation? 
 Top-up HIV-PrEP Give 2 months’ supply after clinical need assessment, 
until next follow-up at month 3 
2 Tenofovir disoproxil fumarate 245mg/emtricitabine 200mg (proprietary name Truvada®)  - renal 
function monitoring 
£8 [£0 + £8] 
 Urinalysis Any suggestion of renal impairment? 
 7% with 1+ protein from urinalysis 
will need serum creatinine or urine 
protein:creatinine ratio test 
UK PROUD study analysis found 7% participants with 1+ 
protein identified from urinalysis (David Dolling, personal 
communications, 28 January 2015) 
 
 
 
 
Month 3/6/9 
 
Total cost for this step: £133 (without Hepatitis C screen, month 3/9); £139 (with Hepatitis C screen, month-6) [routine £115/£122 + 
HIV-PrEP-additional £18] 
 
  Pathway step Data source/notes Pathway cost [routine + 
HIV-PrEP-additional] 
1 Patient consultation £44 [£34 + £10] 
 Routine discussion  
 Review treatment 
adherence/safety/tolerability, sexual 
behaviour assessment, clinical need 
and risk-assessment 
Any HIV-PrEP-related safety concerns? Any bone fracture 
in past 4 months? Review patient adherence, dosing 
pattern/frequency? Any risk compensation? 
 Top-up HIV-PrEP Give 3 months’ supply after clinical need assessment, 
until next follow-up in 3 months 
2 HIV/STI tests £81 (without Hepatitis C 
screen); £87 (with 
Hepatitic C screen in 
50% of patients) 
[£81/£87 + £0] 
 HIV test Serology only 
 STI test (Chlamydia/Gonorrhoea 3 
site plus syphilis test) 
Routine screen 
 Hepatitis C test Routine screen every 6 months (serology test considered 
if there is history of recreational drug use/chem sex), 
assume 50% of patients will be screened due to risk; once 
only at month-6[7,8] 
3 Tenofovir disoproxil fumarate 245mg/emtricitabine 200mg (proprietary name Truvada®)  - renal 
function monitoring 
£8 [£0 + £8] 
 Urinalysis Any suggestion of renal impairment? 
 7% with 1+ protein from urinalysis 
will need serum creatinine or urine 
protein:creatinine ratio test 
UK PROUD study analysis found 7% participants with 1+ 
protein identified from urinalysis (David Dolling, personal 
communications, 28 January 2015) 
 
 
Year 2: For those continuing HIV-PrEP after one year 
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Month 12 
 
Total cost for this step: £162 [routine £121 + HIV-PrEP-additional £41] 
 
  Pathway step Data source/notes Pathway cost [routine + 
HIV-PrEP-additional] 
1 Patient consultation £52 [£34 + £18] 
 Routine discussion  
 Review treatment 
adherence/safety/tolerability, sexual 
behaviour assessment, clinical need 
and risk-assessment  
 
Any HIV-PrEP-related safety concerns? Any bone fracture 
in past 4 months? Review patient adherence, dosing 
pattern/frequency? Any risk compensation? 
 
 Top-up HIV-PrEP Give 3 months’ supply after clinical need assessment, 
until next follow-up in 3 months 
2 HIV/STI tests £81 (without Hepatitis C 
screen); £87 (with 
Hepatitic C screen in 
50% of patients) 
[£81/£87 + £0] 
 HIV test   
 STI test (Chlamydia/Gonorrhoea 3 
site plus syphilis test) 
Routine screen 
 Hepatitis C test Routine screen every 6 months (serology test considered 
if there is history of recreational drug use/chem sex), 
assume 50% of patients will be screened due to risk; once 
only at month-6[7,8] 
3 Tenofovir disoproxil fumarate 245mg/emtricitabine 200mg (proprietary name Truvada®)  - renal 
function monitoring 
£23 [£0 + £23] 
 Serum creatinine Assessment of renal function after 12 months on HIV-
PrEP 
 
 
 
Figure A - 2 GUM pathway for the management of a patient on HIV-PrEP, and routine HIV/STI 
screening; costs are undiscounted; Month 3/6/9 costs will repeat for quarterly appointments in 
subsequent years for MSM continuing HIV-PrEP beyond one year, with renal function assessments 
occurring at an annual frequency 
 
 
GUM pathway for HIV-PrEP 
 
Year 1 
 
Month 0 (Baseline, day start HIV-PrEP – assuming patient comes in for routine HIV/STI consultation and is clinically risk assessed for 
HIV-PrEP) 
 
Total cost for this step: €260 [routine €165 + HIV-PrEP-additional €95] 
 
  Pathway step Data source/notes Pathway cost [routine + 
HIV-PrEP-additional] 
1 Patient consultation €103 [€46 + €57] 
 Routine discussion E.g. check recent sexual behaviour, recreational drug use 
 Assess HIV-PrEP eligibility  
 Check for contraindications Contraindications, medical history 
 Start HIV-PrEP if clinically indicated Give 1 month’s supply 
2 HIV/STI tests €125 [€118 + €7] 
 HIV test negative Routine screen using serology, plus additional Point-Of-
Care-Test in 67% of patients 
 STI test (Chlamydia/Gonorrhoea 3 site 
plus syphilis test) 
Routine screen 
 Hepatitis C test Routine screen every 6 months (serology test considered 
if there is history of recreational drug use/chem sex), 
assume 50% of patients will be screened due to risk[7,8] 
3 Tenofovir disoproxil fumarate 245mg/emtricitabine 200mg (proprietary name Truvada®)  - renal 
function monitoring 
€23 [€0 + €31] 
 Serum creatinine Assessment of renal function prior to HIV-PrEP 
commencement 
 
5 
 
 
 
 
Month 1 
 
Total cost for this step: €71  [routine €0 + HIV-PrEP-additional €71] 
 
  Pathway step Data source/notes Pathway cost [routine + 
HIV-PrEP-additional] 
1 Patient consultation €60 [€0 + €60] 
 Check drug management Include review of adherence, dosing pattern/frequency 
 Sexual behaviour assessment Any risk compensation? 
 Top-up HIV-PrEP Give 2 months’ supply after clinical need assessment, 
until next follow-up at month 3 
2 Tenofovir disoproxil fumarate 245mg/emtricitabine 200mg (proprietary name Truvada®)  - renal 
function monitoring 
€11 [€0 + €11] 
 Urinalysis Any suggestion of renal impairment? 
 7% with 1+ protein from urinalysis 
will need serum creatinine or urine 
protein:creatinine ratio test 
UK PROUD study analysis found 7% participants with 1+ 
protein identified from urinalysis (David Dolling, personal 
communications, 28 January 2015) 
 
 
 
 
Month 3/6/9 
 
Total cost for this step: €181 (without Hepatitis C screen, month 3/9); €189 (with Hepatitis C screen, month-6) [routine €156/€166 + 
HIV-PrEP-additional €24] 
 
  Pathway step Data source/notes Pathway cost [routine + 
HIV-PrEP-additional] 
1 Patient consultation €60 [€46 + €14] 
 Routine discussion  
 Review treatment 
adherence/safety/tolerability, sexual 
behaviour assessment, clinical need 
and risk-assessment 
Any HIV-PrEP-related safety concerns? Any bone fracture 
in past 4 months? Review patient adherence, dosing 
pattern/frequency? Any risk compensation? 
 Top-up HIV-PrEP Give 3 months’ supply after clinical need assessment, 
until next follow-up in 3 months 
2 HIV/STI tests €110 (without Hepatitis 
C screen); €118 (with 
Hepatitic C screen in 
50% of patients) 
[€110/€118 + €0] 
 HIV test Serology only 
 STI test (Chlamydia/Gonorrhoea 3 
site plus syphilis test) 
Routine screen 
 Hepatitis C test Routine screen every 6 months (serology test considered 
if there is history of recreational drug use/chem sex), 
assume 50% of patients will be screened due to risk; once 
only at month-6[7,8] 
3 Tenofovir disoproxil fumarate 245mg/emtricitabine 200mg (proprietary name Truvada®)  - renal 
function monitoring 
€11 [€0 + €11] 
 Urinalysis Any suggestion of renal impairment? 
 7% with 1+ protein from urinalysis 
will need serum creatinine or urine 
protein:creatinine ratio test 
UK PROUD study analysis found 7% participants with 1+ 
protein identified from urinalysis (David Dolling, personal 
communications, 28 January 2015) 
 
 
Year 2: For those continuing HIV-PrEP after one year 
 
Month 12 
 
Total cost for this step: €220 [routine €165 + HIV-PrEP-additional €56] 
 
  Pathway step Data source/notes Pathway cost [routine + 
HIV-PrEP-additional] 
1 Patient consultation €71 [€46 + €24] 
 Routine discussion  
 Review treatment 
adherence/safety/tolerability, sexual 
behaviour assessment, clinical need 
and risk-assessment  
Any HIV-PrEP-related safety concerns? Any bone fracture 
in past 4 months? Review patient adherence, dosing 
pattern/frequency? Any risk compensation? 
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 Top-up HIV-PrEP Give 3 months’ supply after clinical need assessment, 
until next follow-up in 3 months 
2 HIV/STI tests €110 (without Hepatitis 
C screen); €118 (with 
Hepatitic C screen in 
50% of patients) 
[€110/€118 + €0] 
 HIV test   
 STI test (Chlamydia/Gonorrhoea 3 
site plus syphilis test) 
Routine screen 
 Hepatitis C test Routine screen every 6 months (serology test considered 
if there is history of recreational drug use/chem sex), 
assume 50% of patients will be screened due to risk; once 
only at month-6[7,8] 
3 Tenofovir disoproxil fumarate 245mg/emtricitabine 200mg (proprietary name Truvada®)  - renal 
function monitoring 
€31 [€0 + €31] 
 Serum creatinine Assessment of renal function after 12 months on HIV-
PrEP 
 
 
 
7 
 
SUPPLEMENTARY MATERIAL 3 
Background Post-Exposure Prophylaxis following Sexual Exposure (PEPSE) use 
Of the 17,429 high-risk MSM identified in GUMCAD, there was a total of 781 PEPSE courses 
prescribed to 663 individuals in year 2012 [1]. The total number of PEPSE courses is higher than the 
total number of individuals as some individuals had more than one course of PEPSE. By dividing the 
absolute number of PEPSE prescriptions over the total number of high-risk MSM, the proportion of 
overall PEPSE use was 4·48%, which we rounded to 5%. 
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SUPPLEMENTARY MATERIAL 4  
HIV positive care and treatment costs 
Methods 
The cost of care and management of diagnosed HIV cases, excluding antiretroviral drug costs, were 
obtained from Beck et al. (published in 2011, using data from 1996 to 2008) [9]. Information 
extracted from this paper included cost of average use of health care services, and related tests and 
procedures, stratified by CD4+ count at diagnosis (CD4+ count above or below 200). This was then 
applied to information on time to CD4+ recovery to above 200, obtained from the SOPHID (2013) 
annual survey and the new HIV, AIDS and Death databases, and CD4 surveillance system (data year 
2013), to estimate the duration whereby HIV care costs at CD4+ below 200 was applicable [10]. 
 
As HIV care cost estimates from Beck et al. were obtained from older information (year 1996 to 
2008), we expected that the price paid for antiretroviral drugs would have changed over time. 
Hence, the cost of antiretroviral drugs were estimated using a combination of more recent 
information from an NHS England Freedom of Information request (FOI-007334: 2013 to 2015 
London spending data) and the House of Lords Select Committee on HIV and AIDS in the UK written 
evidence (2009/10 data) [11,12]. These estimates covered HIV spend on antiretrovirals in London 
over recent years 2009/10, and 2013/14/15, and were thought to be more representative of the 
current actual price paid for antiretrovirals, as well as reflect the combination of antiretroviral 
regime prescribed, at different prices. 
 
For the purpose of cost-utility analysis, we were interested in costs excluding Value Added Tax (VAT); 
but for budgetary impact, VAT inclusive costs [13]. Value Added Tax is payable for hospital dispensed 
items but zero-rated if dispensed via homecare or community pharmacies [14]. We believed that the 
London reported spend on antiretroviral drug included some amount of VAT i.e. the VAT-net costs 
would be lower. We do not know the proportion of drugs dispensed that had zero-rated VAT to 
calculate the VAT-net antiretroviral drug spend, and appreciate that the reported spend for London 
was higher than actual London VAT-net costs. However, we assumed that the overall VAT-net spend 
on antiretrovirals  for the whole of England would be balanced by the fact that antiretrovirals 
purchased in other parts of England were more expensive than antiretrovirals purchased pan-
London, due to lower purchasing power for the former (an estimated 44% of diagnosed HIV positive 
cases was in London in 2013, contributing to its higher purchasing power) [15]. Therefore, we 
assumed that the reported London spend on antiretrovirals reflect VAT-net spend on antiretrovirals 
for England and used these estimates for HIV treatment costs in our cost-utility analysis. 
 
We assumed that the HIV-related cost of undiagnosed HIV is £0 (€0). In Burns et al., the authors 
estimated that the median number of general practitioner visits in the year before HIV diagnosis in 
237 Africans was two (range 0 to 18) [16]. This level of visit may be lower than the general 
population estimates (around 3x general practitioner consultations per person-year estimated using 
the QRESEARCH general practice database for each year from 1995 to 2006, reported in Figure 5 of 
Hippisley-Cox et al.) [17]. Taken together, we concluded that there is currently no strong evidence to 
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suggest that HIV positive individuals have higher rates of consultation compared with the general 
population in England, hence, no additional costs of undiagnosed HIV. 
 
Results 
HIV infection diagnosis and enrolment into HIV care timeline  
Using years 2011 to 2013 estimated average time between HIV infection date to diagnosis date for 
high-risk MSM, identified from HIV surveillance data, we expected that 52% of all HIV infected 
individuals would be diagnosed within two years of incident infection [10]. Table A - 1 shows the 
proportion of HIV-infected high-risk MSM diagnosed over time, up to 15 years. It was further 
estimated that the median time to CD4+ reduction to below 200 at diagnosis was between 8 years 
(for individuals over 50 years old) and 11·8 years (for those between 15 to 24 years old). We took the 
more conservative assumption and assumed that after year-8, all new diagnoses will present as very 
late diagnosis with CD4+<200. In addition, we assumed that all newly diagnosed individuals will start 
antiretroviral treatment immediately, in line with NHS England ‘treatment as prevention’ policy [18]. 
Analysis based on HIV surveillance data suggested that the time between antiretroviral treatment 
initiation to CD4+ count stabilisation for those with CD4+<200 at diagnosis was 68 days. As a result, 
we applied the higher HIV care costs for CD4+<200 at diagnosis for the period from diagnosis and 
antiretroviral treatment commencement until CD4+ recovery. 
 
Table A - 1 Time to HIV diagnosis, CD4+ count at diagnosis and assumption about diagnosed 
individuals starting and remaining on antiretroviral treatment used in the model 
 
Time 
(Year) 
Proportion of HIV Infections 
Occurring in Year-1 that are 
Diagnosed in Year-1 or in 
Subsequent Rears 
Cumulative 
Proportion 
Diagnosed 
CD4+ 
Count at 
Diagnosis 
Proportion of Diagnosed 
HIV who Started and 
Remained on 
Antiretroviral Treatment 
1 39% 39% >=200 100% 
2 12% 52% >=200 100% 
3 11% 63% >=200 100% 
4 10% 73% >=200 100% 
5 9% 82% >=200 100% 
6 5% 87% >=200 100% 
7 4% 90% >=200 100% 
8 3% 93% >=200 100% 
9 1% 94% <200 100% 
10 1% 95% <200 100% 
11 1% 96% <200 100% 
12 1% 97% <200 100% 
13 1% 98% <200 100% 
14 1% 99% <200 100% 
15 1% 100% <200 100% 
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SUPPLEMENTARY MATERIAL 5 
MSM population size and HIV incidence estimate 
HIV negative MSM population size by risk stratum 
To estimate HIV incidence, we needed estimates of the size of the HIV negative MSM population in 
England. Using GUMCAD 2012 data, we identified 85,505 HIV negative MSM attended GUM clinics in 
England, 17,429 of whom recorded a bacterial STI diagnosis in the previous year and/or during his 
first attendance at the GUM clinic (defined as high-risk) [1]. The balance 68,076 HIV negative MSM 
who attended GUM clinic but who did not have bacterial STI diagnosis were assumed to belong to 
the medium-risk stratum. 
 
We undertook a series of steps to estimate the average number of adult non-GUM attending HIV 
negative MSM in England, i.e. the low-risk stratum. Firstly, the average number of non-GUM 
attending HIV negative MSM aged 15 to 44 years in England and Wales was 244,443 in 2012 [19]. 
Mid-2012 ONS population estimates indicated that 95% of the male population in England and 
Wales was from England; assuming the same distribution for MSM, we estimated the number for 
England alone was 232,221 (for 15 to 44 year olds) [20].  By applying the definition of MSM as men 
in the 2010-12 Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) who reported at 
least one male sexual partner in past five years to the 15 to 75 years male population in England, we 
estimated that 61% of MSM in England were aged between 15 to 44 years [20,21]. Therefore, the 
total number of adult non-GUM-attending HIV negative MSM aged between 15 to 75 years was 
estimated at 380,690. 
 
HIV incidence by risk stratum 
HIV incidence for high- and medium-risk MSM in England was estimated using GUMCAD 2012 data, 
the most recent year whereby complete 1-year follow-up data (up to year 2013) was available at the 
time of our analysis. To calculate HIV incidence in 2012, MSM were followed from their first HIV 
negative test of the calendar year until seroconversion or their last attendance occurring within 12 
months of the first test [22]. In 2012, of the 17,429 high-risk HIV negative MSM attending GUM 
clinics, 6,239 repeat tested for HIV, with 130 seroconversions, and an estimated HIV incidence of 3·3 
per 100 person-years (95% CI 2·8 to 4·9 per 100 person-years) [1,22]. Of the 68,076 medium-risk HIV 
negative MSM attending, 19,953 repeat tested, with 194 seroconversions, and an estimated HIV 
incidence of 1·5 per 100 person-years (95% CI 1·3 to 1·8 per 100 person-years). HIV incidence was 2 
per 100 person-years (95% CI 1·8 to 2·2 per 100 person-years) in the overall HIV negative MSM GUM 
attendees. 
 
In order to estimate HIV incidence among low-risk MSM (defined as non-GUM attending MSM), we 
used incidence estimates from a combination of GUMCAD  and CD4 back calculation [1,23]. The 
number of incident HIV infections for MSM in England and Wales in 2012 was estimated at 2,937 
[23]. Assuming the distribution of HIV positive MSM by country (England/Wales) is the same as the 
male population size for England and Wales i.e. 95% and 5%, respectively, the estimated number of 
incident HIV infections among MSM in England was 2,790. 
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Using an HIV incidence of 2 per 100 person-years among HIV negative MSM attending GUM clinics, 
the absolute number of HIV infections that occurred in 2012 was 1,710 [1,22]. Subtracting this value 
from the total number of infections (i.e. 2,790), gives us an estimated 1,080 infections among non-
GUM attending MSM, an incidence of 0·28 per 100 person-years, which was rounded to 0·30 per 100 
person-years. 
 
Change in high-risk behaviour over time 
We analysed change in high-risk behaviour via the longitudinal five year follow-up of year 2009 high-
risk MSM (recent bacterial STI infection) identified from GUMCAD. Table A - 2 shows that, overall, 
the proportion of MSM identified in the initial (2009) high-risk group who continued to be at high-
risk in each of the subsequent four years (2010 to 2013) decreased rapidly over the first two 
subsequent years (2010 and 2011). 
 
Table A - 2 Subsequent (2010–2013) attendances with bacterial STI of MSM who first attended in 
2009 with bacterial STI (i.e. indicator of high risk), e.g. 2011 attendees (1,172) are all a subset of 
the 11,742 attendees in 2009 and mostly, but not all, a subset of the 3,083 attendees in 2010. 
 
  2009 2010 2011 2012 2013 
Age 
Group 
n 
 
x x/n% x x/n% x x/n% x x/n% 
15-19 518 100% 119 23% 39 8% 22 4% 7 1% 
20-24 2,114 100% 516 24% 206 10% 132 6% 78 4% 
25-29 2,440 100% 651 27% 242 10% 164 7% 131 5% 
30-34 1,842 100% 499 27% 199 11% 151 8% 97 5% 
35-39 1,571 100% 406 26% 145 9% 120 8% 76 5% 
40-44 1,304 100% 326 25% 135 10% 109 8% 77 6% 
45-49 896 100% 270 30% 95 11% 58 6% 49 5% 
50-54 491 100% 134 27% 51 10% 46 9% 35 7% 
55+ 566 100% 162 29% 60 11% 49 9% 39 7% 
All 
Ages 
11,742 100% 3,083 26% 1,172 10% 851 7% 589 5% 
 
The average frequency of high risk was under two years after the initial high-risk year (2009). In 
Table A – 3, all 11,742 MSM were at high risk during the initial 1 year. However, only approximately 
10% (1,199 MSM) of the initial year 11,742 MSM had bacterial STI diagnosed again in two or more of 
the four subsequent years of follow-up (2010 to 2013), as shown in the last row, final three columns 
of Table A – 3. 
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Table A - 3  Number and proportion of high-risk MSM in 2009 subsequently categorised as high-
risk by age group and number of years at high risk over follow-up period from 2010 to 2013 
 
  Recurrent bacterial STI 
  
Number of years at high risk over follow-up period 
2010 to 2013 (x) 
Proportion (x/n%) 
Age 
Group 
n (in 
year 
2009) 
Never 1 2 3 4 Never 1 2 3 4 
15-19 518 369 118 25 5 1 71·24% 22·78% 4·83% 0·97% 0·19% 
20-24 2,114 1,447 470 140 46 11 68·45% 22·23% 6·62% 2·18% 0·52% 
25-29 2,440 1,596 596 170 60 18 65·41% 24·43% 6·97% 2·46% 0·74% 
30-34 1,842 1,185 456 126 62 13 64·33% 24·76% 6·84% 3·37% 0·71% 
35-39 1,571 1,038 378 107 37 11 66·07% 24·06% 6·81% 2·36% 0·70% 
40-44 1,304 859 302 96 35 12 65·87% 23·16% 7·36% 2·68% 0·92% 
45-49 896 561 236 68 24 7 62·61% 26·34% 7·59% 2·68% 0·78% 
50-54 491 306 128 41 8 8 62·32% 26·07% 8·35% 1·63% 1·63% 
55+ 566 347 151 48 17 3 61·31% 26·68% 8·48% 3·00% 0·53% 
All 11,742 7,708 2,835 821 294 84 65·64% 24·14% 6·99% 2·50% 0·72% 
 
The movement of the initial high-risk group to medium- and low-risk were used to derive the 
weighted HIV incidence over time. Figure A - 3 shows this estimated risk of HIV infection for each 
year by 10-year age groups, and for all ages. The HIV incidence for all ages was subsequently used in 
the model. 
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Figure A - 3 Estimated HIV incidence in high-risk MSM, up to year 15 (subsequent incidence stays at 
0·30 per 100 person-years annually until age 75) 
 
 
Impact of initial-year HIV-PrEP on cumulative HIV incidence to age 75 
Estimated future age-specific cumulative HIV incidence to age 75 for MSM at high HIV risk in 2016, 
and the impact of an initial PrEP year, is illustrated in Table A - 4. Slightly greater reductions were 
estimated for the older ages, given less number of lifetime years remaining at risk (up until age 75). 
For example, the cumulative HIV risk to age 75 for a high-risk 35 year-old MSM in year-1 was 16·6%, 
whilst for a 25 year-old it was 19·1%.  Since year-1 HIV risk was 3·3 per 100 person-years, this equals 
19·9% of the cumulative risk to age 75 for the 35 year-old, and 17·3% for the 25 year-old. When 
combined with the age distribution of MSM at high HIV risk eligible for PrEP (Figure A - 1), the 
adjusted average cumulative incidence to age 75 for our 5,000 MSM was equivalent to 16·96% in the 
absence of PrEP. 
 
Table A - 4 Age-specific cumulative HIV incidence to age 75 with or without HIV-PrEP, shown to 
illustrate difference by age; cumulative lifetime incidence for ages 56 and above not shown but 
was considered in the model up until the age of 75 
 
Age in 
2016 
Birth Year 
Cumulative Incidence to Age 75 (%) 
No HIV-PrEP 
HIV-PrEP 86% Effective plus 
20% Risk Compensation 
HIV-PrEP 64% Effective plus 
20% Risk Compensation 
15 2001 21·5 19·2 19·9 
16 2000 21·5 19·2 19·9 
17 1999 21·5 19·2 19·9 
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18 1998 21·5 19·2 19·9 
19 1997 21·5 19·2 19·9 
20 1996 21·5 19·2 19·9 
21 1995 21·2 19·0 19·7 
22 1994 21·0 18·7 19·5 
23 1993 20·7 18·5 19·2 
24 1992 20·5 18·3 19·0 
25 1991 20·3 18·0 18·7 
26 1990 20·0 17·8 18·5 
27 1989 19·8 17·5 18·2 
28 1988 19·5 17·3 18·0 
29 1987 19·3 17·0 17·7 
30 1986 19·1 16·8 17·5 
31 1985 18·8 16·5 17·2 
32 1984 18·6 16·3 17·0 
33 1983 18·3 16·0 16·7 
34 1982 18·1 15·8 16·5 
35 1981 17·8 15·5 16·2 
36 1980 17·6 15·3 16·0 
37 1979 17·3 15·0 15·7 
38 1978 17·1 14·7 15·5 
39 1977 16·8 14·5 15·2 
40 1976 16·6 14·2 15·0 
41 1975 16·3 14·0 14·7 
42 1974 16·1 13·7 14·5 
43 1973 15·8 13·5 14·2 
44 1972 15·6 13·2 14·0 
45 1971 15·3 12·9 13·7 
46 1970 15·1 12·7 13·4 
47 1969 14·8 12·4 13·2 
48 1968 14·6 12·1 12·9 
49 1967 14·3 11·9 12·6 
50 1966 14·1 11·6 12·4 
51 1965 13·8 11·3 12·1 
52 1964 13·5 11·1 11·9 
53 1963 13·3 10·8 11·6 
54 1962 13·0 10·5 11·3 
55 1961 12·8 10·3 11·1 
 
Impact of initial-year HIV-PrEP over the initial decade 
Table A - 5 shows detailed breakdown of number of new HIV infections (undiscounted), discounted 
costs and discounted QALYs, in each of the initial 10 years and over a lifetime, of 5,000 HIV negative 
MSM eligible for HIV-PrEP in the initial high-risk year. From year 2 onwards, after the year-1 PrEP 
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intervention, the number of new HIV infections each year was slightly higher in the group that had 
the intervention compared with those that had not. This is because by preventing new HIV infections 
in year-1, there is a larger number in the intervention group who remained susceptible from year 2 
onwards. 
 
Table A - 5 Contribution of incident HIV cases, costs and QALY losses in the first ten years to the 
overall lifetime estimated number of undiscounted HIV cases, discounted total costs, and 
discounted total QALY losses (no HIV-PrEP versus HIV-PrEP at 86% effectiveness, and HIV-PrEP at 
64%, both assuming 20% HIV incidence increase among those given HIV-PrEP as a form of risk 
compensation); Scenario assuming 5,000 high-risk MSM with HIV incidence of 3·3 per 100 person-
years in the absence of HIV-PrEP, daily oral combination antiretroviral tenofovir disoproxil 
fumarate 245mg/emtricitabine 200mg (proprietary name Truvada®) at a cost of £4,331 (€5,892) 
per person per year 
 
Model Year 1 2 3 4 5 6 7 8 9 10 
overall 
(up to 
year 61) 
Number of HIV Infections (Undiscounted) 
No HIV-PrEP 165 65 42 35 28 23 19 16 14 14 848 
 Proportion of Lifetime HIV 
Infections 
19% 8% 5% 4% 3% 3% 2% 2% 2% 2%   
HIV-PrEP – 86% Effective plus 
Risk Compensation 
28 67 44 36 29 24 20 16 14 14 730 
 Proportion of Lifetime HIV 
Infections 
4% 9% 6% 5% 4% 3% 3% 2% 2% 2%   
HIV-PrEP – 64% Effective plus 
Risk Compensation 
71 66 43 35 29 24 20 16 14 14 768 
 Proportion of Lifetime HIV 
Infections 
9% 9% 6% 5% 4% 3% 3% 2% 2% 2%   
Lifetime HIV Care Costs (Discounted at 3·5% per Annum) 
No HIV-PrEP 
£31·2 
M 
£11·7 
M 
£7·3 
M 
£5·7 
M 
£4·4 
M 
£3·5 
M 
£2·7 
M 
£2·2 
M 
£1·8 
M 
£1·7 
M 
£93·3 M 
No HIV-PrEP 
€ 
42.4 
M 
€ 
15.9 
M 
€ 9.9 
M 
€ 7.8 
M 
€ 6.0 
M 
€ 4.8 
M 
€ 3.7 
M 
€ 3.0 
M 
€ 2.4 
M 
€ 2.3 
M 
€ 126.9 M 
Proportion of Costs of Lifetime 
HIV Infections 
33% 13% 8% 6% 5% 4% 3% 2% 2% 2%   
HIV-PrEP – 86% Effective plus 
Risk Compensation 
£5·2 
M 
£12·1 
M 
£7·5 
M 
£5·8 
M 
£4·6 
M 
£3·6 
M 
£2·8 
M 
£2·2 
M 
£1·8 
M 
£1·7 
M 
£69·2 M 
HIV-PrEP – 86% Effective plus 
Risk Compensation 
€ 7.1 
M 
€ 
16.5 
M 
€ 
10.2 
M 
€ 7.9 
M 
€ 6.3 
M 
€ 4.9 
M 
€ 3.8 
M 
€ 3.0 
M 
€ 2.4 
M 
€ 2.3 
M 
€ 94.1 M 
Proportion of Costs of Lifetime 
HIV Infections 
8% 17% 11% 8% 7% 5% 4% 3% 3% 2%   
HIV-PrEP – 64% Effective plus 
Risk Compensation 
£13·5 
M 
£12·0 
M 
£7·4 
M 
£5·8 
M 
£4·5 
M 
£3·6 
M 
£2·8 
M 
£2·2 
M 
£1·8 
M 
£1·7 
M 
£76·8 M 
HIV-PrEP – 64% Effective plus 
Risk Compensation 
€ 
18.4 
M 
€ 
16.3 
M 
€ 
10.1 
M 
€ 7.9 
M 
€ 6.1 
M 
€ 4.9 
M 
€ 3.8 
M 
€ 3.0 
M 
€ 2.4 
M 
€ 2.3 
M 
€ 104.5 M 
Proportion of Costs of Lifetime 
HIV Infections 
18% 16% 10% 8% 6% 5% 4% 3% 2% 2%   
Lifetime QALY Loss (Discounted at 3·5% per Annum) 
No HIV-PrEP 480 185 117 93 75 60 48 39 33 32 1,829 
Proportion of QALY Loss of 
Lifetime HIV Infections 
26% 10% 6% 5% 4% 3% 3% 2% 2% 2%   
HIV-PrEP – 86% Effective plus 81 190 120 96 77 62 50 40 34 33 1,468 
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Risk Compensation 
Proportion of QALY Loss of 
Lifetime HIV Infections 
5% 13% 8% 7% 5% 4% 3% 3% 2% 2%   
HIV-PrEP – 64% Effective plus 
Risk Compensation 
207 188 119 95 76 61 49 40 33 32 1,582 
Proportion of QALY Loss of 
Lifetime HIV Infections 
13% 12% 8% 6% 5% 4% 3% 3% 2% 2%   
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SUPPLEMENTARY MATERIAL 6 
Sensitivity analyses 
The ICER values generated for the univariate sensitivity analysis of various scenarios considered are 
presented in Table A - 6. The analysis compared no HIV-PrEP versus HIV-PrEP at 86% or 64% 
effectiveness, plus risk compensation (as 20% increase in HIV incidence when given HIV-PrEP). This 
table supplements the tornado diagram presented in the main text (64% effectiveness plus risk 
compensation) and in Figure A - 4 below. 
 
Table A - 6 Output of scenario analyses; gray cells indicate no change from base case scenario 
output; bold texts are base case scenarios (5,000 MSM with HIV incidence of 3·3 per 100 person-
years given HIV-PrEP, 86% or 64% clinical effectiveness, daily oral HIV-PrEP, HIV care costs and 
QALY losses discounted at 3·5% per annum, undiscounted HIV infections presented); *Risk 
compensation in the base case assumes a 20% increase in HIV incidence when given HIV-PrEP 
 
 
No HIV-PrEP HIV-PrEP (86% Effective plus Risk Compensation*) HIV-PrEP (64% Effective plus Risk Compensation*) 
 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
ICERs 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
ICERs 
Base Case Scenario 
Output 
848 £93·34 M 1,829 730 £69·17 M 1,468 -£5,218 768 £76·84 M 1,582 £23,465 
HIV-PrEP Effectiveness: 44% –96% 
44% 
   
802 £83·81 M 1,686 £89,608 802 £83·81 M 1,686 £89,608 
64% 
           
86% 
           
96% 
   
713 £65·69 M 1,415 -£12,997 713 £65·69 M 1,415 -£12,997 
Year-1 HIV Incidence, per 100 Person-Years: 2 to 9 
2 764 £76·69 M 1,576 692 £61·96 M 1,356 £34,275 715 £66·63 M 1,426 £81,304 
3·3 
           
5·2 970 
£117·41 
M 
2,194 786 £79·67 M 1,630 -£27,430 844 £91·64 M 1,809 -£9,058 
9 1,209 
£164·71 
M 
2,911 897 
£100·56 
M 
1,954 -£43,746 996 
£120·92 
M 
2,258 -£32,928 
HIV-PrEP Annual Drug Price, as a Percentage of Current 2016 BNF List Price for Combination Antiretroviral (Tenofovir Disoproxil Fumarate 245mg/Emtricitabine 200mg Tablet): 10% or 
100% 
£433 (10%) 
      
-£59,202 
   
-£55,610 
£4,331 (100%) 
           
Proportion of MSM Given HIV-PrEP Drugs Based on an Intermittent (4 Tablets per 7-Day) Dosing Schedule: 10% or 100% 
0% 
           
100% 
      
-£30,924 
   
-£14,189 
Discount Rate Applied to Future Costs and QALYs: 1·5% or 3·5% 
1·50% 
 
£148·12 
M 
3,576 
 
£113·36 
M 
3,002 -£21,703 
 
£124·39 
M 
3,184 -£3,684 
3·50% 
           
Percentage Reduction in Antiretroviral Treatment Costs from Year 2019 (Used for Treating Diagnosed HIV Infections): 0% to 80% 
0% 
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30% 
 
£79·78 M 
  
£58·95 M 
 
£4,038 
 
£65·56 M 
 
£32,721 
50% 
 
£70·74 M 
  
£52·14 M 
 
£10,208 
 
£58·04 M 
 
£38,891 
80% 
 
£57·17 M 
  
£41·92 M 
 
£19,463 
 
£46·76 M 
 
£48,146 
Risk Compensation (Increased HIV Incidence in Year-1 if Given HIV-PrEP as Proxy for Risk Compensation): 0% to 30% 
0% 
   
726 £68·36 M 1,455 -£7,227 757 £74·75 M 1,551 £13,296 
10% 
   
728 £68·77 M 1,461 -£6,239 762 £75·79 M 1,566 £18,078 
20% 
           
30% 
   
732 £69·58 M 1,474 -£4,161 773 £77·89 M 1,598 £29,582 
Adjustments for GUM clinic change behaviour, such that a higher proportion remain at high-risk for longer: No adjustments or Assume that 30% of High-Risk MSM in the First Year but 
Subsequently Changed Clinic (Hence, Loss to Follow-Up) will Continue to Remain High-Risk in the Second, Third, Fourth, and Fifth Year 
No Adjustments 
           
Assume 30% of High-
Risk MSM in the First 
Year but Subsequently 
Changed Clinic 
Remained High-Risk 
1,308 £158·6 M 2,982 1,203 £136·3 M 2,654 -£97 1,237 £143·3 M 2,758 £31,449 
Disutility After Diagnosis: 0·10 to 0·13 
0·10 
  
1,713 
  
1,377 -£5,606 
  
1,484 £25,212 
0·11 
           
0·13 
  
2,059 
  
1,648 -£4,583 
  
1,779 £20,609 
Disutility between Infection and Diagnosis: 0 or 0·11 
0 
           
0·11 
  
1,967 
  
1,576 -£4,810 
  
1,700 £21,633 
HIV-PrEP-Related GUM Clinic Costs, per Person per Annum: £0 to £406 
£0 
      
-£7,655 
   
£19,895 
£176 
           
£406 
      
-£2,032 
   
£28,131 
 
Table A - 6 Output of scenario analyses; gray cells indicate no change from base case scenario 
output; bold texts are base case scenarios (5,000 MSM with HIV incidence of 3·3 per 100 person-
years given HIV-PrEP, 86% or 64% clinical effectiveness, daily oral HIV-PrEP, HIV care costs and 
QALY losses discounted at 3·5% per annum, undiscounted HIV infections presented); *Risk 
compensation in the base case assumes a 20% increase in HIV incidence when given HIV-PrEP 
 
 
No HIV-PrEP HIV-PrEP (86% Effective plus Risk Compensation*) HIV-PrEP (64% Effective plus Risk Compensation*) 
 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
ICERs 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
ICERs 
Base Case Scenario 
Output 
848 €127 M 1,829 730 €94.1 M 1,468 -€7,099 768 €105 M 1,582 €31,900 
HIV-PrEP Effectiveness: 44% –96% 
44% 
   
802 €114 M 1,686 €121,900 802 €114 M 1,686 €121,900 
64% 
           
86% 
           
96% 
   
713 €89.4 M 1,415 -€17,700 713 €89.4 M 1,415 -€17,700 
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Year-1 HIV Incidence, per 100 Person-Years: 2 to 9 
2 764 
€104.34 
M 
1,576 692 €84.30 M 1,356 €46,600 715 €90.7 M 1,426 €110,600 
3·3 
           
5·2 970 €160 M 2,194 786 €108 M 1,630 -€37,300 844 €125 M 1,809 -€12,300 
9 1,209 €224 M 2,911 897 €137 M 1,954 -€59,500 996 €165 M 2,258 -€44,800 
HIV-PrEP Annual Drug Price, as a Percentage of Current 2016 BNF List Price for Combination Antiretroviral (Tenofovir Disoproxil Fumarate 245mg/Emtricitabine 200mg Tablet): 10% or 
100% 
€589 (10%) 
      
-€80,500 
   
-€75,700 
€5,892 (100%) 
           
Proportion of MSM Given HIV-PrEP Drugs Based on an Intermittent (4 Tablets per 7-Day) Dosing Schedule: 10% or 100% 
0% 
           
100% 
      
-€42,100 
   
-€19,300 
Discount Rate Applied to Future Costs and QALYs: 1·5% or 3·5% 
1·50% 
 
€202 M 3,576 
 
€154 M 3,002 -€29,500 
 
€169 M 3,184 -€5,010 
3·50% 
           
Percentage Reduction in Antiretroviral Treatment Costs from Year 2019 (Used for Treating Diagnosed HIV Infections): 0% to 80% 
0% 
           
30% 
 
€109 M 
  
€80.2 M 
 
€5,490 
 
€89.2 M 
 
€44,500 
50% 
 
€96.2 M 
  
€70.9 M 
 
€13,900 
 
€79.0 M 
 
€52,900 
80% 
 
€77.8 M 
  
€57.0 M 
 
€26,500 
 
€63.6 M 
 
€65,500 
Risk Compensation (Increased HIV Incidence in Year-1 if Given HIV-PrEP as Proxy for Risk Compensation): 0% to 30% 
0% 
   
726 €93.0 M 1,455 -€9,830 757 €102 M 1,551 €18,100 
10% 
   
728 €93.6 M 1,461 -€8,490 762 €103 M 1,566 €24,600 
20% 
           
30% 
   
732 €94.7 M 1,474 -€5,660 773 €106 M 1,598 €40,300 
Adjustments for GUM clinic change behaviour, such that a higher proportion remain at high-risk for longer: No adjustments or Assume that 30% of High-Risk MSM in the First Year but 
Subsequently Changed Clinic (Hence, Loss to Follow-Up) will Continue to Remain High-Risk in the Second, Third, Fourth, and Fifth Year 
No Adjustments 
           
Assume 30% of High-
Risk MSM in the First 
Year but Subsequently 
Changed Clinic 
Remained High-Risk 
1,308 €216 M 2,982 1,203 €185 M 2,654 -€132 1,237 €195 M 2,758 €42,800 
Disutility After Diagnosis: 0·10 to 0·13 
0·10 
  
1,713 
  
1,377 -€7,630 
  
1,484 €34,300 
0·11 
           
0·13 
  
2,059 
  
1,648 -€6,240 
  
1,779 €28,000 
Disutility between Infection and Diagnosis: 0 or 0·11 
0 
           
0·11 
  
1,967 
  
1,576 -€6,540 
  
1,700 €29,400 
HIV-PrEP-Related GUM Clinic Costs, per Person per Annum: €0 to €552 
€0 
      
-€10,400 
   
€27,100 
€240 
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€552 
      
-€2,770 
   
€38,300 
 
 
Figure A - 4 Univariate sensitivity analyses of PrEP ICER around base case* for plausible ranges† of 
key parameters. 
 
 
 
Note: 
*
Base case (negative ICER = PrEP is cost-saving), set at 86% PrEP effectiveness level and a 20% increase in HIV incidence in 
those given PrEP due to risk compensation (see main text). 
†
Extremes of parameter ranges shown at either end of horizontal bars. 
 
Other scenarios explored 
Adjustment for attendance at another GUM clinic with consequent loss to longitudinal follow-up and 
impact on lifetime HIV risk 
Individuals attending the same GUM clinic will hold the same local patient identifier number in 
GUMCAD and can be followed longitudinally. However, because GUMCAD is pseudo-anonymised, 
when individuals moved clinic, their local patient identifier number would change. This meant that in 
our longitudinal follow-up of our initial high-risk group from 2009, up to 2013, there may be those 
who remained at high- or medium-risk but changed clinic, and whom we would have assumed they 
no longer attend GUM clinics and were at low-risk. A preliminary analysis of an enhanced version of 
GUMCAD that captured data on previous attendance at another clinic found that, of the 2,962 MSM 
who responded to this question, 483 (16·3%) attended another GUM clinic in the past year, and 
another 442 (14·9%) attended in the last 1 to 5 years (H Mohammed, Public Health England, 
personal communications, 30 June 2015). Thus, we explored a scenario whereby 30% (combined 0 
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to 5 years previous attendance at another clinic) of our initial high-risk group continued to remain 
high-risk throughout the first five years. This adjustment resulted in an increased lifetime HIV 
incidence as more individuals continue to remain at high-risk. Consequently, the HIV prevention 
effect of an initial high-risk year on HIV-PrEP on this increased cumulative lifetime HIV incidence was 
reduced, resulting in less favourable ICER (see Table A - 7). 
 
Table A - 7 Comparison of ICER output of base case and after adjusting for potential loss to follow-
up following movement out of the initial GUM clinic; shaded empty cells mean there is no change 
from base case (take the base case scenario output); *Risk compensation in the base case assumes 
a 20% increase in HIV incidence when given HIV-PrEP 
 
 
No HIV-PrEP HIV-PrEP (86% Effective plus Risk Compensation*) HIV-PrEP (64% Effective plus Risk Compensation*) 
 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
ICERs 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
ICERs 
Base Case Scenario 
Output 
848 
£93·34 M 
(€127) 
1,829 730 
£69·17 M 
(€94.1 M) 
1,468 
-£5,218 (-
€7,100) 
768 
£76·84 M 
(€105 M) 
1,582 
£23,465 
(€31,900) 
Adjustments for movement out of initial GUM clinic with consequent loss to longitudinal follow-up, such that a higher proportion should remain at high-risk for longer: No adjustments or 
Assume that 30% of High-Risk MSM in the First Year but Subsequently Changed Clinic (Hence, Loss to Follow-Up) will Continue to Remain High-Risk in the Second, Third, Fourth, and Fifth 
Year 
No Adjustments 
           
Assume 30% of High-
Risk MSM in the First 
Year but Subsequently 
Changed Clinic 
Remained High-Risk 
1,308 
£158·6 M 
(€215.8 
M) 
2,982 1,203 
£136·3 M 
(€185.4 
M) 
2,654 -£97 1,237 
£143·3 M 
(€195 M) 
2,758 
£31,449 
(€42,800) 
 
Duration of remaining lifetime at risk 
We further explored scenarios whereby after 10, 20, or 30 years, our initial high-risk group of MSM 
stopped having any residual risk of HIV. The impact on the ICER was minimal in these scenarios, since 
the large majority of the new HIV infections occurred in the initial 10 years, and costs and QALY 
losses in the future were increasingly discounted (see Table A – 5) for proportion of new HIV 
infections, costs and QALY losses occurring in the first 10 years versus lifetime; and Table A - 8 for 
overall ICER output comparison). 
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Table A - 8 Impact on ICER output by considering shorter duration of remaining lifetime at risk; 
shaded empty cells mean there is no change from base case (take the base case scenario output); 
*Risk compensation in the base case assumes a 20% increase in HIV incidence when given HIV-
PrEP 
 
 
No HIV-PrEP HIV-PrEP (86% Effective plus Risk Compensation*) HIV-PrEP (64% Effective plus Risk Compensation*) 
 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
ICERs 
Number 
of HIV 
Infections 
HIV Care 
Costs 
QALY 
Losses 
ICERs 
Base Case Scenario 
Output 
848 
£93·34 M 
(€127 M) 
1,829 730 
£69·17 M 
(€94.1 M) 
1,468 
-£5,218 
(€7,100) 
768 
£76·84 M 
(€105 M) 
1,582 
£23,465 
(€31,900) 
Lifetime HIV Incidence: Stops Being At Risk After 10, 20, 30 Years or Lifetime Risk 
Stops Being At Risk 
After 10 Years 
422 
£72·06 M 
(€98 M) 
1,161 292 
£47·30 M 
(€64.4 M) 
781 
-£6,547 (-
€8,910) 
333 
£55·16 M 
(€75.1 M) 
902 
£20,706 
(€28,200) 
Stops Being At Risk 
After 20 Years 
553 
£84·16 M 
(€115 M) 
1,431 427 
£59·74 M 
(€81.3 M) 
1,058 
-£5,759 (-
€7,840) 
467 
£67·49 M 
(€91.8 M) 
1,176 
£22,054 
(€30,000) 
Stops Being At Risk 
After 30 Years 
673 
£90·23 M 
(€123 M) 
1,625 550 
£65·97 M 
(€89.8 M) 
1,258 
-£5,376 (-
€7,310) 
589 
£73·67 M 
(€98 M) 
1,374 
£22,855 
(€31,100) 
Lifetime Risk 
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